用环孢素A联合方案治疗骨髓增生异常综合征

The efficacy of cyclosporine a regimens in the treatment of myelodysplastic syndrome

目的 :探讨用环孢素 A联合方案治疗骨髓增生异常综合征 (MDS)的疗效。方法 :对 43例 MDS患者进行分组施治 ,低危组 12例采用环孢素 A联合康力隆、维甲酸口服 ,部分患者应用 EPO进行治疗 ;高危组 31例采用环孢素 A联合康力隆、维甲酸口服 ,同时加用小剂量或标准剂量化疗。结果 :低危组总有效率为 75 % ,基本缓解率为 42 % ;高危组总有效率为 74.2 % ,完全缓解率为 5 4.8%。结论 :用环孢素 A联合诱导分化剂、小剂量 (或标化量 )化疗及细胞因子分型施治 ,可以明显提高 MDS的疗效 。

Objective:To explore the efficacy of cyclosporine A regimens for treating patients with myelodysplastic syndrome.Method:Forty three patients with myelodysplastic syndrome were divided into low risk group (RA, RARS,n=12) and high risk group (RAEB?RAEB-T,n=31) and different cyclosporine A based regimens were used in each group.The patients in the low risk group were treated with cyclosporine A combined with all trans retinoic acid (ATRA),stanozolol, and erythropoietin (EPO).In patients in the high risk group, the regimen used in the low risk group was prescribed with low dose or standard dose chemotherapy.Result:The overall efficacy and remission rate were 75% and 42% in the low risk group, and 74.2 % and 54.8 % in the high risk group, respectively.Conclusion:The cyclosporine A based regimens is efficacious for treating patients with myelodysplastic syndrome and might improve the clinical outcome in such patients.